Your Messages Inbox
Your Article Summary
See Latest ArticlesGenentech ordered to halt Rituxan trials
PharmExec, 06/19/09
An arbitrator has ruled that Genentech must halt several trials until Biogen Idec says they can move forward. In 2006, the two companies, filed for arbitration to settle whether Genentech could develop follow-on drugs to the cancer and rheumatoid arthritis drug Rituxan, without Biogen's approval. The arbitrator ruled that three of the trials must be halted, although a Phase III trial for the arthritis biologic ocrelizumab can continue.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
Clinical Cancer Research, 10/19/09
A Randomized Trial of Doxycycline for Mansonella perstans Infection
New England Journal of Medicine, 10/08/09
Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention
Trials, 10/28/09
Article Search
Sponsor